Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference




Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 44^th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Adaptive Biotechnologies’ management is scheduled to present on Monday, January 12, 2026, at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com

INVO Fertility Aligns Executive Leadership Structure to Support Growth Strategy




INVO Fertility Aligns Executive Leadership Structure to Support Growth Strategy

Terah Krigsvold to replace Andrea Goren as CFO, who is named chief business officer and CEO of INVO Centers LLC to focus on growth efforts

SARASOTA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) — INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced changes to its executive leadership team to align its human resources with the Company’s growth strategy focused on the acquisition and establishment of fertility clinics and ancillary organizations.

Terah Krigsvold, who has served as INVO’s controller since December 2020, has been appointed as the Company’s new chief financial officer, replacing Andrea Goren. Mr. Goren, who has served as INVO chief financial officer since July 2021, has been appointed as chief business officer, as well as chief executive officer of INVO Centers LLC, the Company’s wholly owned subsidiary focused on fertility clinics.

“As we continue to grow our presence in the fertility sector and based on Terah and Andrea’s commitment, hard work and growth over the past five years, this realignment of roles strengthens our ability to execute our plan to grow the business and reach profitability,” said Steve Shum, CEO of INVO. “I have worked with Terah for the past seven years and am thrilled at the progress she has demonstrated over that time. This promotion is very well deserved and ensures continuity, as well as keeping our finance and accounting functions in a strong pair of hands. With this change, Andrea is now able to focus more of his time on leading the execution of our primary growth strategy, acquisitions, and, in due course, new clinic launches. Andrea has worked on approximately $1 billion of financing and acquisition transactions in his career and is ideally suited to manage the negotiations and complex legal and diligence aspects of our acquisition and new clinic efforts. Andrea also will continue in his roles of managing our legal function and supporting our investor, shareholder, and related activities.”

About INVO Fertility

We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have two operational INVO Centers in the United States and one IVF clinic. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman’s body. The IVC procedure provides patients with a more connected, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination. For more information, please visit invofertility.com.

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.

For more information, please contact:

INVO Fertility, Inc.
Steve Shum, CEO
978-878-9505
sshum@invofertility.com

Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com

INVO Fertility Aligns Executive Leadership Structure to Support Growth Strategy




INVO Fertility Aligns Executive Leadership Structure to Support Growth Strategy

Terah Krigsvold to replace Andrea Goren as CFO, who is named chief business officer and CEO of INVO Centers LLC to focus on growth efforts

SARASOTA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) — INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced changes to its executive leadership team to align its human resources with the Company’s growth strategy focused on the acquisition and establishment of fertility clinics and ancillary organizations.

Terah Krigsvold, who has served as INVO’s controller since December 2020, has been appointed as the Company’s new chief financial officer, replacing Andrea Goren. Mr. Goren, who has served as INVO chief financial officer since July 2021, has been appointed as chief business officer, as well as chief executive officer of INVO Centers LLC, the Company’s wholly owned subsidiary focused on fertility clinics.

“As we continue to grow our presence in the fertility sector and based on Terah and Andrea’s commitment, hard work and growth over the past five years, this realignment of roles strengthens our ability to execute our plan to grow the business and reach profitability,” said Steve Shum, CEO of INVO. “I have worked with Terah for the past seven years and am thrilled at the progress she has demonstrated over that time. This promotion is very well deserved and ensures continuity, as well as keeping our finance and accounting functions in a strong pair of hands. With this change, Andrea is now able to focus more of his time on leading the execution of our primary growth strategy, acquisitions, and, in due course, new clinic launches. Andrea has worked on approximately $1 billion of financing and acquisition transactions in his career and is ideally suited to manage the negotiations and complex legal and diligence aspects of our acquisition and new clinic efforts. Andrea also will continue in his roles of managing our legal function and supporting our investor, shareholder, and related activities.”

About INVO Fertility

We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have two operational INVO Centers in the United States and one IVF clinic. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman’s body. The IVC procedure provides patients with a more connected, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination. For more information, please visit invofertility.com.

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.

For more information, please contact:

INVO Fertility, Inc.
Steve Shum, CEO
978-878-9505
sshum@invofertility.com

Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com

Positron Corporation Raises $2 Million to Expand Market Presence and Growth Initiatives




Positron Corporation Raises $2 Million to Expand Market Presence and Growth Initiatives

Buffalo, NY, Dec. 30, 2025 (GLOBE NEWSWIRE) — Positron Corporation (OTC: POSC) (the “Company”), a leading molecular imaging medical device company specializing in Positron Emission Tomography (PET) and PET-CT imaging systems and clinical support services, is pleased to announce it has accepted $2.0 million in capital in exchange for 1,333,333 shares of the Company’s stock.

The proceeds from the financing will be used to accelerate Positron’s commercial expansion and advance key strategic objectives, including product development, regulatory activities, and pursue new markets. The capital raise further enhances the Company’s ability to meet increasing demand for advanced cardiac PET imaging solutions.

Adel Abdullah, President of Positron Corporation stated, “We are encouraged by the continued support from investors, which reflects growing confidence in Positron’s strategy and long-term growth potential,” Mr. Abdullah added, “An improved balance sheet positions the Company to expand its market presence, increase system placements, and advance the next generation of our PET-CT technology.”

The Company believes this capital will support its near-term growth initiatives while positioning Positron for longer-term opportunities, including new markets and new product introductions and clinical and service offerings.

ABOUT POSITRON CORPORATION

Positron Corporation is a medical technology company that co-develops, manufactures, and commercializes advanced PET and PET-CT imaging systems and integrated imaging solutions, combining molecular imaging hardware, software, and clinical and training services for nuclear medicine healthcare providers across North America.

Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging, the gold standard in cardiac diagnostics. Positron’s innovative PET/PET-CT technologies, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine.

Positron’s PET and PET-CT imaging systems and distinct market position are substantial advantages unique to Positron that will facilitate the adoption of cardiac PET and the growth of the nuclear imaging market. Positron’s PET-CT(s) will enable nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine. Positron’s PET-CT systems will also enable the Company to fully service and meet the demands of the vast oncology imaging segment of nuclear medicine. 

Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its co-developer, supplier, and R&D venture with Shenyang Intelligent Neuclear Technology Co. a subsidiary of Neusoft Medical Systems.  

Please visit the Company’s website at: www.positron.com

FORWARD-LOOKING STATEMENTS

This press release contains statements which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Positron Corporation, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Some of the risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political and regulatory conditions; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; and new product introductions by our competitors. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results even if new information becomes available in the future.

FOR FURTHER INFORMATION, please visit the company’s website at www.positron.com, or contact: investor@positron.com

Investor Relations Contact:
Skyline Corporate Communications Group, LLC
1177 Avenue of the Americas, 5th Floor
New York, New York 10036

iSpecimen Inc. Announces Pricing of ~$5.5 Million Private Placement




iSpecimen Inc. Announces Pricing of ~$5.5 Million Private Placement

WOBURN, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it entered into a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $5.5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.

In connection with the offering, the Company will issue 6,875 shares of newly designated Series C Convertible Preferred Stock (the “Preferred Stock”) at a price of $800 per share. Each share of Preferred Stock is convertible into shares of the Company’s common stock based on a $1,000 stated value per Preferred Stock share and a conversion price of 85% of the closing price of the common stock as of the date prior to each conversion date.

The Company intends to use the net proceeds from the offering for marketing, working capital, and general corporate purposes.

The offering is expected to close on or about December 31, 2025, subject to the satisfaction of customary closing conditions.

E.F. Hutton & Co. is acting as the exclusive placement agent in connection with the offering.

Additional details regarding the offering will be available in a Form 8-K to be filed by the Company with the Securities and Exchange Commission (the “SEC”).

The securities to be issued in connection with the offering described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”), and Regulation D promulgated thereunder and have not been registered under the 1933 Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the 1933 Act and such applicable state securities laws. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investors, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock issuable upon conversion of the shares of Preferred Stock.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About iSpecimen

iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com. 

Safe Harbor Statement

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning the development of our company. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The reader is cautioned not to rely on such forward-looking statements. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including the uncertainty regarding future commercial success, risks and uncertainties associated with market conditions and the Company’s ability to satisfy the closing conditions related to the offering. These and other factors may cause our actual results to differ materially from any forward-looking statements. Forward-looking statements are only predictions and actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 14, 2025, as well as other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iSpecimen specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

info@ispecimen.com

Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary 




Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary 

Tainan City, Taiwan, Dec. 30, 2025 (GLOBE NEWSWIRE) — Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced that on December 23, 2025, it entered into an agreement (the “Agreement”) with an unrelated third party, Wei Ha Hui (the “Buyer”), pursuant to which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed (HK) Limited, a Hong Kong company and a wholly owned subsidiary of the Company (the “Hong Kong Subsidiary”), for an aggregate purchase price of US$23,000 based on a valuation report commissioned by the Company, subject to the terms and conditions set forth in the Agreement.

All intellectual property owned by the Hong Kong subsidiary, including intellectual property owned by Shanghai Sglcell Biotech Co., Ltd., a wholly owned subsidiary of the Hong Kong subsidiary, was transferred to the Buyer at the closing of this transaction on December 23, 2025.

Dr. Yi Lu, CEO of the Company, commented: “In light of evolving regulatory requirements on clinical trials and data in China, and to accelerate development and commercialization of our products and solutions, we decided to divest the assets of Hong Kong and Shanghai subsidiaries. All clinical trials will now be centralized and conducted through our Taiwan subsidiary, which we believe will be part of our strategic realignment.”

About Advanced Biomed Inc.

Advanced Biomed Inc. is a Nevada corporation specializing in innovative biomedical technologies for cancer detection and precision medicine.

Operating through the subsidiary in Taiwan, the Company has developed a proprietary microfluidic platform that integrates semiconductor and biotechnology to enable advanced circulating tumor cell (CTC) detection, enrichment, and analysis. Its portfolio includes devices, biochips, and designed for cancer screening, diagnosis, treatment selection, and prognosis assessment, with regulatory clearances in progress in Taiwan and plans for future global expansion.

For more information, please visit: www.advanbiomed.com.

Forward‑Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the documents filed with the United States Securities and Exchange Commission (the “SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:
Advanced Biomed Inc.
Steven I-Fang Cheng
Email: info@advbiomedicine.com
invest@advbiomedicine.com

Akari Therapeutics Issues 2025 End of Year Letter to Shareholders




Akari Therapeutics Issues 2025 End of Year Letter to Shareholders

TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today issued the following letter to shareholders from its President and Chief Executive Officer, Abizer Gaslightwala.                                   

Dear Fellow Shareholders,

As 2025 concludes, I am pleased to reflect on a year of meaningful progress and significant achievements towards creating best-in-class ADCs to transform current cancer therapies. With each forward step and each new milestone, we are advancing our mission to bring our innovative and uniquely designed ADCs to cancer patients with the highest unmet needs. The scientific and operational strides made this year have positioned Akari for what we believe will be a pivotal and transformational year ahead for the Company.

2025: Building Our Foundation — A Year of Strategic Milestones and Execution

Advancing a New Class of ADCs with a Novel Payload, PH1

This year Akari solidified a clear scientific roadmap focused on progressing our innovative ADCs built on our proprietary PH1 payload, a spliceosome-modulating mechanism. This represents a fundamentally different approach compared to traditional ADC payloads, as PH1 was specifically designed to overcome key limitations of existing ADC payload classes by delivering:

• Potent cytotoxic activity to kill tumor cells without being vulnerable to traditional cancer resistant mechanisms affecting current ADC payloads
• Unique immune activation of both the innate and adaptive systems to broaden and deepen anti-tumor responses
• A differentiated safety profile compared to current ADCs with traditional payloads

These attributes align with Akari’s strategy to build ADC therapies that kill cancer cells directly and most importantly, harness and engage the powerful immune system to attack the cancer broadly. This 1-2 punch has been demonstrated to improve therapeutic durability, depth of response and remissions and significantly extend survival of preclinical models relative to current ADC therapies, which we believe will translate into superior outcomes for cancer patients in future clinical trials.
  
Progress on Lead Program: AKTX-101

Our lead program, AKTX-101, advanced significantly in 2025 with a number of key wins.
AKTX-101 is a Trop2 targeted ADC that delivers the PH1 payload using a proprietary non-cleavable linker designed to drive potent tumor cell killing, engage the immune system through both innate and adaptive responses to cancer tumors, and minimize off-target effects. We continued to build the preclinical data story and conviction for AKTX-101 and the PH1 payload as we prepare to enter clinical studies:

• AKTX-101 demonstrated significant activity in pancreatic cancer driven by KRAS, one of the most deadly mutations in pancreatic, lung and colon cancers.
• PH1 payload demonstrated significant activity against a key driver in prostate cancer, AR-V7, opening up future opportunities in this large patient population.
• These data build on the powerful results for AKTX-101 that demonstrate compelling activity in both urothelial (bladder) and gastric cancer preclinical models.
• The safety profile of AKTX-101, as tested in non-human primates, highlights clear differentiation relative to current Trop2 ADCS that use conventional payloads, and suggests the potential for improved tolerability in clinical settings.

GMP Manufacturing Initiated with a World-Class Partner to Enable Upcoming Phase 1 Clinical Trials for AKTX-101

A watershed moment in 2025 was the initiation of our partnership with WuXi XDC to begin manufacturing GMP-grade clinical product for AKTX-101 to support our future clinical studies. WuXi XDC is a global leader in ADC development and manufacturing and has a track record for producing ADCs with the highest quality, speed and reliability for partners. This milestone is critical for Akari for a number of reasons:

• Marks the transition of Akari from a preclinical discovery company into a clinical focused biotechnology player
• Contributes to the production of high-quality, clinical-grade ADC for Phase 1 studies
• Signals confidence that one of the best global partners wants to work with Akari to advance its innovative ADC and payload into clinical trials

Akari believes that partnering with WuXi XDC enables it to quickly advance AKTX-101 toward first-in-human trials planned for late 2026 or early 2027, subject to regulatory clearance.

Intellectual Property and Scientific Engagement

Throughout 2025, we continued to bolster our intellectual property portfolio and the value of our payload platform with new provisional patent filings protecting the unique aspects of the PH1 payload. Of note, we filed three new patents around our ADC payload within the last two quarters of 2025, driven by the high productivity and efficiency of our research team.

Additionally, Akari presented promising immuno-oncology data at the most prominent immuno-oncology research meeting in the world, the Society for Immunotherapy Cancer (SITC). The submission was noted as one of the top 150 submissions at the conference, and garnered great enthusiasm and excitement from both academic researchers and pharmaceutical scientists on how splicing modulation via our PH1 ADC payload is a unique and effective way to attack cancer.

Finally, as we look to maximize the potential of our PH1 payload potential, we established a world-class Scientific Advisory Board to engage and guide Akari on our PH1 payload ADC strategy. These key advisors will play a critical role in helping us optimize how we develop our promising technology to maximize its impact in cancer patients moving forward. We plan on announcing more details about this group of well-known advisors in the near future.

Strengthening Our Operating Model

In parallel with the notable scientific and research advancements outlined, we took important steps in 2025 to strengthen Akari’s operating model and capital discipline. Our approach to capital infusions throughout 2025 enabled our R&D milestones noted previously, key patent filings, and the initiation of key manufacturing and preclinical activities to start the path to Phase 1 clinical studies with AKTX-101. These efforts also position the Company to pursue additional financing and partnership opportunities with both strategic investors and pharmaceutical/biotechnology companies as they also look at our upcoming catalysts and milestones with AKTX-101.   We also made significant progress in reducing operating expenses post the close of the merger, while building our R&D capabilities through an efficient and scalable network of key vendors, consultants and suppliers.

Why 2026 Is Expected to Be a Transformational Year

Looking ahead, I am very excited to have Akari progressing to critical inflection points that could significantly increase the Company’s value and clinical impact:

Key Catalysts and Milestones on the Horizon

• Regulatory interactions with FDA for feedback on our planned Phase 1 trial
• Presentation of differentiating data on AKTX-101 vs other Trop2 ADCs
• Completion of CMC and non-clinical work for AKTX-101 to enable IND/CTA submissions at the end of 2026/ early 2027
• Initiation of the Phase 1 clinical trial in late 2026 or early 2027, subject to regulatory clearance
• Continued partnership discussions with pharmaceutical companies on our unique and differentiated PH1 payload/ADC approach and key catalysts forthcoming

Entering Phase 1 clinical studies will be a unique inflection point for Akari as an ADC oncology company, a milestone that historically correlates with increased visibility, investor interest and potential strategic partnerships with large pharmaceutical companies or strategic investors. Our excitement as a team for 2026 is unbounded, and we look forward to executing with urgency.

We remain grateful for your continued trust and support in our path forward as an oncology ADC company, and we are excited by the potential ahead. Thank you for your continued belief in our mission and focus on developing therapies that could make a significant difference for cancer patients in their continued fight. We look forward to updating you throughout 2026 as we work diligently and with impatience every day to bring innovative therapies to patients, and reward you as shareholders for your conviction and belief in our plan and execution.

Sincerely,

Abizer Gaslightwala
President & Chief Executive Officer
Akari Therapeutics, Plc

About Akari Therapeutics

Akari Therapeutics is an oncology biotechnology company developing next-generation spliceosome payload antibody drug conjugates (ADCs). Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The Company is generating validating data on its novel payload PH1 to continue advancing its lead asset, as well as other undisclosed targets with this novel payload.

For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements 

This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and any other diseases, and ultimately bring therapies to patients; the Company’s targets, plans, objectives or goals for future operations, including those related to its product candidates. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com

TerrAscend Increases Retail Footprint in New Jersey with Closing of Union Chill Dispensary Transaction




TerrAscend Increases Retail Footprint in New Jersey with Closing of Union Chill Dispensary Transaction

Expands New Jersey retail footprint to four dispensaries 

Dispensary generates over $11 million in annualized revenue and is expected to be immediately accretive to EBITDA and cashflow

Transaction further solidifies TerrAscend’s leadership position in state

TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) — TerrAscend Corp. (the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today announced that its consolidated entities (“TerrAscend”) closed on the previously announced transaction with Union Chill Cannabis Company LLC (“Union Chill”), a high-performing dispensary in Hunterdon County. The transaction expands TerrAscend’s retail footprint to four dispensaries in New Jersey and is expected to be immediately accretive to EBITDA and cashflow.

In May 2025, TerrAscend signed an agreement with Union Chill for total consideration of $13 million consisting of $9 million in the form of convertible notes bearing interest at 6.5% for an option to purchase 35% of Union Chill (“Option”) and $4 million in cash upon the exercise of the Option. The transaction conforms to New Jersey’s regulatory framework, which facilitates investment opportunities for diversely owned businesses. Upon exercise of the Option and additional conditions, the transaction will allow the Company to fully consolidate the business in its financial results and increase TerrAscend’s consolidated retail footprint to a total of 20 dispensaries across five U.S. states and Canada.

“Union Chill will strengthen our leadership position in New Jersey with the addition of a high-performing dispensary strategically located in Hunterdon County,” said Jason Wild, Executive Chairman of TerrAscend. “This dispensary is well situated with limited competition within a 10-mile radius and is currently generating over $11 million in annualized revenue. With the integration of our premium brand portfolio, we expect to drive increased sales, margins, and long-term value.”

About TerrAscend Corp.
TerrAscend Corp. is a leading TSX-listed cannabis company with interests across the North American cannabis sector, including operations in Pennsylvania, New Jersey, Maryland, Ohio, and California through TerrAscend Growth Corp. and retail operations in Canada. TerrAscend operates The Apothecarium and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. TerrAscend’s cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use markets. The Company owns or licenses several synergistic businesses and brands including The Apothecarium, Cookies, Ilera Healthcare, Kind Tree, Legend, State Flower, Wana, and Valhalla Confections. For more information visit www.terrascend.com.

Caution Regarding Cannabis Operations in the United States
Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.

While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against the Company. The enforcement of federal laws in the United States is a significant risk to the business of the Company and any proceedings brought against the Company thereunder may adversely affect the Company’s operations and financial performance.

Forward-Looking Information

This press release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and include, but not limited to, statements with respect to the Company’s expectations for its financial results (including as a result of the Union Chill transaction); the Company’s operational improvements, growth and expansion opportunities in 2025 and 2026; the anticipated timing to exercise the Option to acquire Union Chill; statements with respect to the Company’s expectations with respect to its business outlook, financial profile, and operational efficiencies; and its market opportunities, growth prospects in existing markets, and M&A strategy. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, current and future market conditions; risks related to federal, state, provincial, territorial, local and foreign government laws, rules and regulations, including federal and state laws in the United States relating to cannabis operations in the United States; and the risk factors set out in the Company’s most recently filed MD&A, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca and in the section titled “Risk Factors” in the Company’s Annual Report for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 6, 2025, as updated by its Quarterly Reports on Form 10-Q.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether, as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.

For more information regarding the Company:
Ziad Ghanem
Chief Executive Officer
IR@terrascend.com
689-345-4114

Investor Relations Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
Valter@KCSA.com
212-896-1254

Easy Environmental Solutions Announces Availability Of EasyFEN Liquid Microbial Production System




Easy Environmental Solutions Announces Availability Of EasyFEN Liquid Microbial Production System

Company prepares for shipment of first EasyFEN™ system to Africa as part of global deployment strategy

MANKATO, Minn., Dec. 30, 2025 (GLOBE NEWSWIRE) — Easy Environmental Solutions, Inc. (OTC: EZES) today announced the completed construction and availability of the EasyFEN Liquid Microbial Production System, with the first system to be shipped and deployed to East Africa. Subsequent units are in process for deployment into Central America, Europe, West Africa, and the United States.  

The patent pending technology of the EasyFEN™ system will extract juices from local biomass and seed it with proprietary microbials to produce Terreplenish, a 100% organic soil amendment designed to restore soil health and enhance agricultural productivity. Each EasyFEN™system will process up to 17,500 tons of green biomass, food waste, and crop residue each year. This biomass and food waste will be transformed into as much as 2.7 million gallons of Terreplenish…enough to treat up to 1.35 million acres (546,000 hectares) of farmland every year…and which University of Missouri research calculates to be enough to feed 16 million people per year…over 43,000 per day.

The fully automated system will be remotely monitored for consistent performance and quality control…allowing for regional deployment and utilization of green waste and food waste from local communities.

By converting food and crop waste rather than allowing decomposition in field and landfills, each system prevents methane emissions equivalent to removing approximately 30,000 cars from the road per year.

“Throughout the world, the need for reliable, locally controlled production systems to feed millions of people is immediate,” said Mark Gaalswyk, Founder & CEO of Easy Environmental. “With the EasyFEN, regions can produce nutrient-rich liquid microbial solutions themselves, using their own crop waste streams. We believe this model can be scaled across the world exponentially, and we are committed to advancing it.”

“Real food security begins when a nation can nourish its own soil,” added Bakry Osman, Director of Africa Operations for Easy Environmental. “The EasyFEN puts that power back in the hands of the countries we serve — producing nutrient-rich liquid microbial fertilizers locally, reliably, and at scale. This isn’t just a new input. It’s a new foundation for agricultural independence in the 21st century.”

More than just a technological breakthrough, the EasyFEN™system represents the powerful intersection of humanitarian impact and economic opportunity. As the world faces severe food insecurity, countries are in critical need of sustainable agricultural solutions in order to prevent millions from suffering and dying from starvation. By aligning the mission to end world hunger and reduce greenhouse gas emissions with a fully sustainable, high-return investment model, Easy FEN technology drives sustainable agriculture, food security, and economic growth worldwide, offering hope and lasting change to those who need it most.

About Easy Environmental Solutions, Inc.

Easy Environmental Solutions, Inc. (OTC: EZES), formerly Digital Utilities Ventures, Inc., is an innovative company developing modular technologies to solve major world problems. With a strong goal for sustainability and efficiency, EZES aims to provide solutions for various industries through its unique approach to manufacturing and technology development.

Forward-Looking Statements

This press release contains discussions that may constitute ‘forward-looking’ statements. Often these statements contain the words “believe,” “estimate,” “project,” “expect” or similar expressions. These statements are made in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements.

Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company’s current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company’s periodic reports filed with OTC Markets. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Contact:

Mark K. Gaalswyk, CEO – Mark@easyenviro.com
Nick Vincent, Sales Operations Manager – nickvincent@easyenviro.com
Bill Bliler – Director, Business Development – billbliler@easyenviro.com

www.easyenergysystems.com
www.easyenergyfinance.com
www.easyenviro.com
Phone: 952-400-6045
Email: info@easyenviro.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/afd61793-4ff0-4f5c-8c11-9c6b4c99224b
https://www.globenewswire.com/NewsRoom/AttachmentNg/8ce1dd5e-3b19-4f06-ace8-2e503db7c8f8

Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108




Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108

PALI-2108 is the first and only PDE4 inhibitor in development targeting
the terminal ileum and colon for treatment of ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) to address significant unmet medical needs

Ongoing development of PALI-2108 across FSCD and UC, with Phase 2 IND submission planned for H1 2026

Carlsbad, CA, Dec. 30, 2025 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that the Japan Patent Office (JPO) has granted a key patent covering PALI-2108, the Company’s lead, gut-microbiota-activated PDE4 B/D inhibitor being advanced for fibrostenotic Crohn’s disease (FSCD) and moderate to severe ulcerative colitis (UC).

The patent, titled “Gut Microbiota-Activated PDE4 Inhibitor Prodrug,” provides composition-of-matter protection for PALI-2108 in Japan. The base patent term extends into 2041 and is eligible for patent term extension based on regulatory review timelines. This issuance expands Palisade Bio’s growing global intellectual property estate supporting PALI-2108 and its broader platform of locally activated PDE4 inhibitor prodrugs.

“Securing this Japanese patent for PALI-2108 is an important milestone as we continue to strengthen the IP foundation for our IBD portfolio,” said J.D. Finley, Chief Executive Officer of Palisade Bio. “Japan represents one of the world’s largest and most commercially significant markets for inflammatory bowel disease, and patients with UC and FSCD continue to face limited targeted treatment options. This patent not only reinforces the global reach of our technology but also supports the long-term opportunity of PALI-2108 as a differentiated, locally-acting therapy. We believe PALI-2108 has the potential to meaningfully improve outcomes for IBD patients in Japan and worldwide.”

PALI-2108 has recently completed a Phase 1a SAD/MAD and FE, followed by a Phase 1b cohort study in UC and is currently being evaluated in an ongoing Phase 1b cohort study in FSCD. Data from these studies are expected to support Phase 2 Investigational New Drug (IND) submissions to the U.S. Food and Drug Administration (FDA) in the first half of 2026.

About PALI-2108

PALI-2108 is an orally administered, prodrug engineered for local delivery of phosphodiesterase-4 (PDE4) inhibition to the terminal ileum and colon. The prodrug molecule is gut-restricted and pharmacologically inactive until it reaches the lower intestine, where it is cleaved by bacterial enzymes to release its active PDE4 inhibitor metabolite directly at the site of inflammation and fibrosis. This targeted and slow-release design prevents absorption through the upper gut, achieves sustained local exposure and a longer half-life that enables once-daily dosing, and is engineered to produce a blunted peak plasma concentration to improve the overall therapeutic index. Together, these properties are intended to maximize anti-inflammatory and anti-fibrotic effects while minimizing systemic exposure and reducing class-related tolerability issues, such as nausea and headache, that have limited systemic PDE4 inhibitors.

About Palisade Bio

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”) is a clinical-stage biopharmaceutical company advancing a next generation of, once daily, oral PDE4 inhibitor prodrugs designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases.

The Company’s lead program, PALI-2108, is a locally-bioactivated PDE4 inhibitor prodrug being developed for moderate-to-severe Ulcerative Colitis (UC) and Fibrostenotic Crohn’s Disease (FSCD), two diseases with limited non-immunosuppressive therapy options. In a recently reported Phase 1b trial, PALI-2108 achieved a 100% clinical response in the UC cohort, with no serious adverse events, favorable tolerability and pharmacokinetics consistent with sustained localized activation, low systemic exposure, and controlled release within the GI tract.

Palisade Bio is now advancing towards a Phase 2 clinical study in UC designed to evaluate clinical remission, response and pharmacodynamic biomarkers over 12 weeks, with an extension phase assessing maintenance of remission. In addition, the Company is preparing to initiate studies in FSCD to further characterize PALI-2108’s safety, pharmacology and therapeutic benefit across inflammatory bowel disease indications. For more information, please go to www.palisadebio.com.

Forward Looking Statements

Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: statements regarding the timing and results of clinical trials, the potential mechanisms of action and therapeutic benefits of PALI-2108, and plans for regulatory submissions. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials; the Company’s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, activity, dosing or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 24, 2025, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com